Core Insights - EB Development has acquired over 90% of Eurobio Scientific's share capital, reaching 90.01% ownership [2][3] Company Overview - Eurobio Scientific is a prominent player in in vitro diagnostics, focusing on transplantation, immunology, and infectious diseases [4] - The company provides diagnostic tests and dedicated reagents for research laboratories, including pharmaceutical and biotechnology firms [4] - Eurobio Scientific operates with approximately 320 employees and has production units in the Paris region, Germany, the Netherlands, and the USA, along with subsidiaries in several European countries [4] Shareholder Information - The main shareholders of Eurobio Scientific include IK Partners, NextStage AM, and its directors Jean-Michel Carle and Denis Fortier [5] - Eurobio Scientific's shares are listed on Euronext Growth Paris and are part of various indices, including Euronext Growth BPI Innovation and Next Biotech [5]

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO N ...

Core Insights - The article highlights the investment strategies and achievements of Paul Franke, a seasoned investor with 38 years of trading experience, emphasizing his contrarian stock selection style and algorithmic analysis [1] Group 1: Investment Strategy - Paul Franke developed a system called "Victory Formation," which focuses on identifying supply/demand imbalances through specific stock price and volume movements [1] - The strategy recommends investors to maintain a diversified portfolio of at least 50 well-positioned stocks and to use stop-loss levels of 10% or 20% on individual investments to enhance market outperformance [1] Group 2: Stock Selection Focus - The "Bottom Fishing Club" articles target deep-value stocks or those showing significant positive technical momentum reversals [1] - The "Volume Breakout Report" articles analyze stocks that exhibit positive trend changes supported by strong price and volume trading activity [1]

Core Viewpoint - Novo Nordisk is facing significant challenges in the weight loss drug market, particularly as its CEO Lars Fruergaard Jorgensen steps down amid increasing competition from Eli Lilly's Zepbound, which is rapidly gaining market share [2][4][6]. Company Developments - The abrupt resignation of CEO Lars Fruergaard Jorgensen comes as Novo Nordisk's Wegovy loses ground to Eli Lilly's Zepbound, which analysts believe could lead to a market worth over $150 billion by the early 2030s [2][3]. - Novo Nordisk's stock has seen a decline of over 50% in the past year, resulting in a loss of more than $300 billion in market value, while Eli Lilly's shares have surged approximately 800% during the same period [6][5]. - The Novo Nordisk Foundation has urged for an accelerated CEO succession and greater board representation, indicating internal pressure for change [7][8]. Market Competition - Eli Lilly's Zepbound has surpassed Wegovy in new U.S. prescriptions as of early March 2024, capturing an estimated 40% of the U.S. weight loss drug market [11][10]. - Zepbound and Eli Lilly's diabetes drug Mounjaro now account for over half of U.S. prescriptions for GLP-1s, compared to the combined 46% share of Wegovy and Ozempic [10][12]. - Analysts have noted that Zepbound leads to more weight loss than Wegovy, indicating a shift in physician and patient preference [12]. Future Strategies - The new CEO will need to address the challenges of closing the gap with Eli Lilly, launching new weight loss drugs before Wegovy's patents expire, and managing the impact of Medicare drug price negotiations [3][9]. - Novo Nordisk has filed for U.S. approval of an oral version of semaglutide, which could tap into a market projected to be worth $50 billion in the coming years [15][16]. - The company is also exploring partnerships for small-molecule obesity drugs, although these products are still in early development and years away from market entry [21][22]. Strategic Shifts - Despite the CEO transition, Novo Nordisk maintains that its strategy remains unchanged, focusing on its strong product portfolio [19][20]. - Recent licensing deals suggest a potential pivot towards oral small molecule solutions for obesity, indicating a shift from its traditional peptide-based therapeutics [20][21]. - Novo Nordisk's new drug acquisition from United Laboratories International could compete with Eli Lilly's retatrutide, which is in late-stage clinical trials, potentially entering the market sooner [23].

Group 1: Earnings Performance - Target Hospitality reported a quarterly loss of $0.05 per share, missing the Zacks Consensus Estimate of a loss of $0.02, compared to earnings of $0.20 per share a year ago, representing an earnings surprise of -150% [1] - The company posted revenues of $69.9 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.93%, but down from year-ago revenues of $106.67 million [2] - Over the last four quarters, Target Hospitality has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - Target Hospitality shares have lost about 26.5% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at -$0.10 on $59.43 million in revenues for the coming quarter and -$0.25 on $273.03 million in revenues for the current fiscal year [7] - The estimate revisions trend for Target Hospitality is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Group 3: Industry Context - The Leisure and Recreation Services industry, to which Target Hospitality belongs, is currently in the top 36% of over 250 Zacks industries, suggesting a positive outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Nvidia is well-positioned to continue its earnings-beat streak in the upcoming report, having consistently surpassed earnings estimates in recent quarters [1][5]. Earnings Performance - For the last reported quarter, Nvidia achieved earnings of $0.89 per share, exceeding the Zacks Consensus Estimate of $0.84 per share, resulting in a surprise of 5.95% [2]. - In the previous quarter, Nvidia was expected to post earnings of $0.75 per share but delivered $0.81 per share, achieving a surprise of 8% [2]. Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Nvidia, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5][8]. - The current Earnings ESP for Nvidia is +3.87%, suggesting analysts are optimistic about its near-term earnings potential [8]. Zacks Rank and Success Rate - Nvidia holds a Zacks Rank of 3 (Hold), which, when combined with a positive Earnings ESP, indicates a high probability of beating earnings estimates, with a success rate of nearly 70% for stocks with this combination [6][8].

Core Viewpoint - Burlington Stores (BURL) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, continuing a strong trend of surpassing expectations in previous quarters [1]. Earnings Performance - Burlington Stores has consistently exceeded earnings estimates, with an average surprise of 4.45% over the last two quarters [2]. - In the last reported quarter, the company achieved earnings of $4.07 per share, surpassing the Zacks Consensus Estimate of $3.76 per share by 8.24% [3]. - In the previous quarter, Burlington was expected to earn $1.54 per share but reported $1.55 per share, resulting in a surprise of 0.65% [3]. Earnings Estimates and Predictions - Recent estimates for Burlington Stores have been trending upward, indicating positive sentiment among analysts [6]. - The Zacks Earnings ESP for Burlington is currently +1.78%, suggesting that analysts are optimistic about the company's earnings prospects [9]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) indicates a high likelihood of another earnings beat, with historical data showing that this combination leads to positive surprises nearly 70% of the time [7][9]. Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [8]. - A positive Earnings ESP enhances the predictive power for earnings surprises, while a negative value does not necessarily indicate an earnings miss [10].

Core Viewpoint - Build-A-Bear (BBW) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, continuing a strong trend of surpassing expectations in previous quarters [1][6]. Earnings Performance - Build-A-Bear has consistently exceeded earnings estimates, with an average surprise of 4.45% over the last two quarters [2]. - In the last reported quarter, the company achieved earnings of $1.59 per share, surpassing the Zacks Consensus Estimate of $1.52 per share by 4.61% [3]. - In the previous quarter, Build-A-Bear reported earnings of $0.73 per share against an expectation of $0.70 per share, resulting in a surprise of 4.29% [3]. Earnings Estimates and Predictions - Recent estimates for Build-A-Bear have been revised upwards, indicating a positive outlook for the company's earnings [6]. - The Zacks Earnings ESP for Build-A-Bear is currently +0.97%, suggesting that analysts are optimistic about the company's earnings prospects [9]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) indicates a high likelihood of another earnings beat [9]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [7]. - The Earnings ESP metric compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [8].

Core Insights - Seanergy Maritime Holdings Corp (SHIP) is positioned to potentially continue its earnings-beat streak in upcoming reports, having surpassed earnings estimates by an average of 16.36% in the last two quarters [1][5]. Earnings Performance - For the last reported quarter, Seanergy Maritime Holdings achieved earnings of $0.34 per share, exceeding the Zacks Consensus Estimate of $0.28 per share, resulting in a surprise of 21.43% [2]. - In the previous quarter, the company was expected to report earnings of $0.62 per share but delivered $0.69 per share, yielding a surprise of 11.29% [2]. Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Seanergy Maritime Holdings, with a positive Zacks Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5][8]. - The current Earnings ESP for the company stands at +12.64%, suggesting increased analyst optimism regarding its near-term earnings potential [8]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7].

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell even higher, with the expectation that established trends will continue [1] Company Overview: Mineralys Therapeutics, Inc. (MLYS) - MLYS currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [4] Performance Metrics - Over the past week, MLYS shares increased by 4.78%, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 0.92% [6] - In a longer timeframe, MLYS shares have shown a monthly price change of 14.98%, significantly higher than the industry's 3.03% [6] - Over the last quarter, MLYS shares surged by 60.56%, while the S&P 500 index declined by 2.26% during the same period [7] - Year-to-date, MLYS shares are up 18.08%, compared to the S&P 500's increase of 13.85% [7] Trading Volume - MLYS has an average 20-day trading volume of 794,549 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, two earnings estimates for MLYS have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$4.36 to -$3.77 [10] - For the next fiscal year, two estimates have also moved upwards with no downward revisions [10] Conclusion - Given the strong performance metrics and positive earnings outlook, MLYS is positioned as a promising investment opportunity with a Momentum Score of A and a Zacks Rank of 2 (Buy) [12]